New KEYTRUDA ® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting

Dateline City: KENILWORTH, N.J. Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate  Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new findings from KEYNOTE-001, including updated response rates, duration of response data and three-year OS data with KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, in patients with unresectable or metastatic melanoma. Language: English Contact: Merck Media: Pamela Eisele, 267-305-3558 An Phan, 908-255-6325 or Investors: Teri Loxam, 908-740-1986 Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Related Links:

Authors: Li J, Yan S, Wu N PMID: 30023129 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
In conclusion, this study makes clear that lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells through up-regulating c-myc expression via enhancing its combination with TGF2BP1 protein. Overall, our study illustrates that lncRNA THOR/c-myc molecular cascade might be another potent target for retinoblastoma treatment.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
AbstractEfforts to prevent melanoma, especially for those at elevated risk for the disease, should ideally begin during childhood. However, there are few preventive interventions targeting children who are at higher risk for melanoma due to a family history of the disease. Further, there are no educational interventions that aim to help these at-risk children understand their risk for melanoma and the ways in which preventive behaviors, such as sun protection, can mitigate their risk. The current paper describes a multidisciplinary team ’s process for creating a developmentally appropriate educational intervention ab...
Source: Journal of Cancer Education - Category: Cancer & Oncology Source Type: research
Condition:   Intervention:   Drug: omaveloxolone Sponsor:   Reata Pharmaceuticals, Inc. Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions“InterPreT Cancer Survival” is presented as an educational tool which engages the user through interactive features to improve the understanding of commonly reported cancer survival statistics. The tool has received positive feedback from a Cancer Research UK patient sounding board and there are further plans to incorporate more disease characteristics, e.g. stage.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
ConclusionsWe found some evidence that higher intake of folate from food only was associated with a modest increased risk of cutaneous melanoma. However, since other factors related to dietary folate intake may account for the observed association, our findings warrant further investigation.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Eye Cancer: Intraocular (Uveal) Melanoma Treatment
Source: eMedicineHealth.com - Category: General Medicine Source Type: news
I took our cat, Peekaboo, to the vet two days ago, around lunchtime. When her new CAT scan results came in, my vet told me that, even though the melanoma had spread a bit in the past two weeks, the cancer hadn’t gone into the jawbone yet. She recommended that we do the surgery. After asking a few obvious but almost-impossible-to-answer questions (will the surgery PROLONG HER LIFE without impacting her QUALITY OF LIFE, blablabla), I called Stefano, and we both agreed it was our only choice at this point, even though there really aren’t any guarantees: this sort of cancer is very aggressive, so it may come back a...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll cat surgery feline oral cancer feline oral melanoma Source Type: blogs
Melanoma brain metastases (MBM) often cause morbidity and mortality for stage IV melanoma patients. An ongoing randomised phase III trial (NCT01503827 – WBRT-Mel) evaluates the role of adjuvant whole brain rad...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Interleukin-like EMT inducer (ILEI, FAM3C) is a secreted factor that contributes to the epithelial-to-mesenchymal transition (EMT), a cell-biological process that confers metastatic properties to a tumor cell. However, very little is known about how ILEI is regulated. Here we demonstrate that ILEI is an in vivo regulator of melanoma invasiveness and is transcriptionally up-regulated by the upstream stimulatory factor-1 (USF-1), an E-box–binding, basic-helix-loop-helix family transcription factor. shRNA-mediated knockdown of ILEI in melanoma cell lines attenuated lung colonization but not primary tumor formation. We a...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Gene Regulation Source Type: research
More News: Melanoma | Merck | Pharmaceuticals | Skin Cancer | Yervoy